
About Esphera SynBio
Esphera SynBio is a Healthcare company based in Ottawa (Canada) founded in 2022 by John Bell, Brian Lichty, and Carolina Ilkow. Esphera SynBio has raised $2.37 million across 3 funding rounds from investors including Government of Canada, FACIT and GKCC. Its chief executive, as recorded, is Brian Lichty. Esphera SynBio offers products and services including Modified Exosomes and Transgenes. Its focus areas include Life Sciences, Immunotherapy, Diversified and Oncology.
Company details
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
- Headquarters Ottawa, Canada
- Founders John Bell, Brian Lichty, Carolina Ilkow
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website espherasynbio.ca
- Social LinkedIn
- Total Equity Funding$2.37M (USD)
in 3 rounds
- Latest Funding Round$365.5K (USD), Seed
May 2026
- InvestorsGovernment of Canada
& 3 more
Products & Services of Esphera SynBio
Esphera SynBio offers a comprehensive portfolio of products and services, including Modified Exosomes and Transgenes.
Technology for designing exosomes with targeting and payloads for disease treatment
Encodes proteins for exosome modification in therapeutic applications
Funding Insights of Esphera SynBio
Esphera SynBio has successfully raised a total of $2.37M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $365.5 thousand completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.37M
- Total Rounds 3
- Last Round Seed β $365,500
- Investors Count 4
All 3 funding rounds of Esphera SynBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $365,500 | Seed | β | β | |
| Jan 2025 | $2M | Seed | β | β | |
| Dec 2024 | Grant | β | β |
4 investors in total: 4 institutional.
Investors in Esphera SynBio
Esphera SynBio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Government of Canada, FACIT and GKCC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Invests in oncology startups, scales ventures, and drives clinical trials in Ontario. | 2014 | facit.ca | Toronto, Canada | |
Online platform providing access to a wide range of government services and information | 1867 | canada.ca | Ottawa, Canada | |
| ontario.ca |
Investor details for Esphera SynBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Esphera SynBio
3 people are tracked at Esphera SynBio (3 in leadership).
| Name | Role | Group |
|---|---|---|
John Bell | Co-Founder | Leadership |
Brian Lichty | Co-Founder & CEO | Leadership |
Carolina Ilkow | Co-Founder & CSO | Leadership |
Complete people profiles for Esphera SynBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Esphera SynBio
3 dated milestones of Esphera SynBio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Esphera SynBio is founded.
- Funding First funding round.
- Funding Latest funding round, Seed, of $366K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Esphera Synbio
Complete news archive for Esphera SynBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Esphera SynBio
Esphera SynBio was founded in 2022 and raised its 1st funding round 2 years after it was founded.
Esphera SynBio is headquartered in Ottawa, Canada. It is registered at Ottawa, Ontario, Canada.
Brian Lichty is the CEO of Esphera SynBio, as recorded in our data. They have also founded this company.
Esphera SynBio is a funded company, having raised a total of $2.37M across 3 funding rounds to date.
Developer of cancer and immunoregulatory treatments using synthetic biology. The platform focuses on altering tumor-derived exosomes in vivo such that they become immunostimulatory, antigen-bearing TME and patient-specific cancer vaccines.
Esphera SynBio offers Modified Exosomes and Transgenes.
Esphera SynBio has 4 investors. Key investors include Government of Canada, FACIT, GKCC, and Ontario Canada.
